Bio X Cell RecombiMAb Recombinant Antibodies

With more than 700 antibodies, ≤0.5 EU/mg endotoxin levels and nearly 30,000 peer reviewed citations since 1997, Bio X Cell is the trusted global leader in functional, in vivo ready antibodies for cancer, immunology and immuno oncology research.

Why Recombinant Antibodies Matter for In Vivo Studies

Traditional hybridoma derived antibodies introduce hidden risks into preclinical in vivo research. Hybridoma cell lines can suffer from genetic drift, gene loss and gene mutations that lead to lot to lot variability over time. In addition, because hybridomas are made using immunised animals, typically rats or hamsters, the species of the antibody cannot be changed. Repeated injection of rat IgG into mice can trigger an immune response, reduced effectiveness or hypersensitivity reactions, undermining study integrity and animal welfare.

RecombiMAb antibodies solve these problems by encoding a single heavy and a single light chain with a defined DNA and amino acid sequence, ensuring consistent reproduction of the same molecule across experiments, models and research teams.

Three Pillars of the RecombiMAb Solution

Built for purpose. Trusted in vivo clones with decades of citation history, re-engineered through modern recombinant production for consistency, reproducibility and reliable performance.

Fc switched for lower immunogenicity. Mouse or human matched IgG constant regions reduce immunogenicity in murine and humanised mouse models, leading to fewer immune driven artefacts, less exposure drift and more consistent repeat dosing.

Advanced effector function modulation. Isotype selection (IgG1 or IgG2a) to control Fc effector functions, plus optional Fc silencing mutations such as LALA-PG and D265A that reduce binding to endogenous Fcγ receptors and complement, allowing a true assessment of target biology.

In Vivo Ready Quality You Can Trust

Every RecombiMAb antibody is manufactured to strict in vivo specifications and is free of preservatives, stabilizers and carrier proteins. Each lot is QC tested against the following criteria:

• Exceptional purity, ≥95%, validated by SDS-PAGE
• Binding validation by immunoblot for every lot
• Ultra low endotoxin, ≤0.5 EU/mg, tested per lot. Lower endotoxin levels are available on request via technical support
• Pathogen free, screened against an extensive panel of murine pathogens, with results reported on product specific datasheets to meet IACUC and Animal Facility requirements
• Low protein aggregation, guaranteed at less than 5% of total protein, supporting predictable antibody behaviour in immune integrated studies

Research Advantages At a Glance

RecombiMAb is designed for in vivo immunology and oncology studies where data quality, timeline confidence and program continuity matter:

• Clearer biology, because Fc engineered and Fc silent formats help avoid unintended immune effects
• More reliable repeat dosing, because species matched Fc reduces immunogenicity and exposure drift
• Lower background noise, because low endotoxin and low aggregation reduce cytokine artefacts
• Fewer mid-study changes, because sequence defined reagents support lot to lot consistency
• Easier scale up, because consistent single lot supply enables cohort expansion without changing reagents

Built for Translational Research Workflows

RecombiMAb antibodies are aligned with the most demanding in vivo immunology and immuno oncology applications, including mechanism of action validation studies, immune checkpoint blockade and agonist studies, PK/PD and repeat dose models, immune cell depletion and modulation, combination immunotherapy research, and translational and comparative in vivo studies.

Featured Ready to Ship Functional Recombinant Antibodies

Bio X Cell offers pre-engineered formats for the most cited targets in immune-oncology research:

The portfolio also covers checkpoint pathway, combination immunotherapy, immune activation, immune cell depletion, myeloid and macrophage biology, tumor microenvironment, cytokine and immune signaling and immune trafficking targets, plus ready to ship anti mouse bispecifics including PD-1 x CTLA-4, LAG-3 x PD-L1, PD-1 x PD-L1, CD3 x CD20, PD-1 x VEGF-A and PD-L1 x VEGF.

A Growing RecombiMAb Portfolio

Bio X Cell currently offers more than 70 recombinant products across 45 in vivo proven clones, with over 80 additional antibodies in development. Researchers can already access multiple Fc variants of the same clone. For example, the recombinant anti PD-1 RMP1-14 family is available as Rat IgG2a(CP182), Mouse IgG2a (CP157, CP153, CP151) and Mouse IgG1 (CP162, CP002), making it easy to match the format to the experimental question.

Custom Recombinant Antibodies Built to Your Specifications

Beyond the catalog, Bio X Cell offers full custom services from clone or sequence to study ready antibody. This includes engineering services such as bispecifics and advanced formats (KIH, IgG-scFv, fragments, Fc fusions), species and isotype switching, and Fc mutagenesis. Mammalian expression is available in HEK or CHO cells with flexible scale from pilot studies up to 20 L and beyond. Purification options include Protein A/G and tag-based purification, polishing and endotoxin quantification. QC and formulation services include aggregation and binding analysis, murine pathogen screening, and custom concentration, buffer and vialing options.

Order RecombiMAb Through Bio-Connect in the BeNeLux

Backed by nearly 30 years of antibody excellence and PhD level scientific support, Bio X Cell helps researchers achieve consistent, reliable results. Bio-Connect is the Bio X Cell distributor in the Benelux and supplies all Bio X Cell products in this region, with fast local delivery, in house technical support and expert advice for researchers across the Netherlands, Belgium, Luxembourg and beyond.

For questions or assistance, please contact our helpdesk at tech@bio-connect.nl.